RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5328.67M
Enterprise Value 362.68M
Trailing P/E N/A
Forward P/E 1-3.25
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)37.13
Price/Book (mrq)1.46
Enterprise Value/Revenue 37.08
Enterprise Value/EBITDA 6-1.11

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-45.73%
S&P500 52-Week Change 3-0.33%
52 Week High 316.06
52 Week Low 36.30
50-Day Moving Average 37.90
200-Day Moving Average 39.89

Share Statistics

Avg Vol (3 month) 3185.3k
Avg Vol (10 day) 3199.36k
Shares Outstanding 544.53M
Float 25.28M
% Held by Insiders 120.39%
% Held by Institutions 150.07%
Shares Short (Jul 15, 2019) 41.61M
Short Ratio (Jul 15, 2019) 46.03
Short % of Float (Jul 15, 2019) 45.15%
Short % of Shares Outstanding (Jul 15, 2019) 43.61%
Shares Short (prior month Jun 14, 2019) 42.13M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-681.14%

Management Effectiveness

Return on Assets (ttm)-13.37%
Return on Equity (ttm)-22.25%

Income Statement

Revenue (ttm)8.85M
Revenue Per Share (ttm)0.20
Quarterly Revenue Growth (yoy)40.00%
Gross Profit (ttm)-41.29M
EBITDA -56.51M
Net Income Avi to Common (ttm)-54.31M
Diluted EPS (ttm)-1.26
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)241.94M
Total Cash Per Share (mrq)5.43
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)12.89
Book Value Per Share (mrq)5.07

Cash Flow Statement

Operating Cash Flow (ttm)-46.59M
Levered Free Cash Flow (ttm)-28.78M